“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa

02 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce new positive data in the Company’s ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more…

12 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting (“AGM”) held earlier today were duly passed.

Read more…

10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.

Read more…

21 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its Scientific Advisory Board.

Read more…

14 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.

Read more…

2 August 2019: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2019 and the Notice of the 2019 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.

Read more…

A copy of the Annual Report can be found by clicking here

16 July 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

Read more…

12 July 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Nicholas Adams in the newly created role of VP Business Development & Alliance Management.

Read more…

18 June 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will webcast the analyst briefing on the day of its preliminary results, Thursday 11 July 2019.

Read more…